about
Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor geneNovel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variantsMicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancerInduction of TIG3, a putative class II tumor suppressor gene, by retinoic acid in head and neck and lung carcinoma cells and its association with suppression of the transformed phenotypeEvidence that the human death receptor 4 is regulated by activator protein 1Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cellsThe synthetic retinoid CD437 selectively induces apoptosis in human lung cancer cells while sparing normal human lung epithelial cellsInternational Union of Pharmacology. LX. Retinoic acid receptorsInternational Union of Pharmacology. LXIII. Retinoid X receptorsKnockout of the tumor suppressor gene Gprc5a in mice leads to NF-kappaB activation in airway epithelium and promotes lung inflammation and tumorigenesisPotential misinterpretation of data on differential gene expression in normal and malignant cells in vitro.Expression of interleukin-1 receptor-associated kinase-1 in non-small cell lung carcinoma and preneoplastic lesionsBiological activity of celecoxib in the bronchial epithelium of current and former smokers.Comparative functional genomics analysis of NNK tobacco-carcinogen induced lung adenocarcinoma development in Gprc5a-knockout miceDifferential inhibition of protein translation machinery by curcumin in normal, immortalized, and malignant oral epithelial cells.Mortality in the randomized, controlled lung intergroup trial of isotretinoinA Gprc5a tumor suppressor loss of expression signature is conserved, prevalent, and associated with survival in human lung adenocarcinomasHigh-dose fenretinide in oral leukoplakia.Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma.Proteomics-based identification of proteins secreted in apical surface fluid of squamous metaplastic human tracheobronchial epithelial cells cultured by three-dimensional organotypic air-liquid interface method.Characterization of the murine orphan G-protein-coupled receptor gene Rai3 and its regulation by retinoic acid.Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers.Retinoids and their receptors in cancer development and chemoprevention.A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis.Molecular based treatment of oral cancer.Mechanistic contribution of ubiquitous 15-lipoxygenase-1 expression loss in cancer cells to terminal cell differentiation evasion.Enhancement of lung tumorigenesis in a Gprc5a Knockout mouse by chronic extrinsic airway inflammation.Apoptosis as a novel target for cancer chemoprevention.Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system.Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention.Proliferative changes in the bronchial epithelium of former smokers treated with retinoids.Validation of a novel statistical model for assessing the synergy of combined-agent cancer chemoprevention.Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward.G-protein coupled receptor family C, group 5, member A (GPRC5A) expression is decreased in the adjacent field and normal bronchial epithelia of patients with chronic obstructive pulmonary disease and non-small-cell lung cancer.Cancer chemoprevention and mitochondria: targeting apoptosis in transformed cells via the disruption of mitochondrial bioenergetics/redox state.
P50
Q24300355-B11808F6-A0F5-4C0E-B954-9E9DDF5B9C55Q24624194-E26682B0-936A-4A73-94FC-1633E3C25E66Q24629078-6CEF4684-3758-4FA9-AC2E-B76B00AFC42AQ28189279-E0911C63-3293-461E-B1F3-3E42E9453A24Q28206926-0D566CD8-03F3-4DE6-BB71-CCA9C6D1FAACQ28210401-4F300FA2-C7B2-4CB9-8C85-D16595C233D9Q28214817-8F46265A-AFFB-48B7-AE35-D4416916D797Q28276127-4F1B5D69-E4BA-41AC-B47E-D2A140638399Q28276158-9A77890F-EA72-441B-80B7-BF881DEAB3ABQ28396291-70F42E72-F645-4C03-8F15-CDC117CDDEEFQ31155012-1533F4C0-C0CB-4700-8AFB-5D0DE4ABB8FCQ33610340-0DB47804-9AE3-46C9-B507-A34C0E9A5532Q33640402-7FB3AF4C-251A-4B90-96F5-064DF9EF7346Q33649612-ACB3AA6D-302B-498B-99A3-F1A5DC452983Q33708023-678B4C5C-DF0F-4EED-A7C2-FCACBD02A69DQ33895618-04E348AF-FCF4-4169-AAA9-B9CE7B806B8FQ33918887-72448977-7C6D-443E-913D-B8026D668653Q34164825-F1449F9E-4099-4DBD-8708-2263C1B99CD6Q34180253-9FDBF738-2205-4A08-84D9-1275BBB5E763Q34216404-A62E5992-354B-43BA-977D-12921F4A64E6Q34287785-2982EB5A-2B03-496B-BC84-856B2F244F74Q34310451-3C9E1CF0-7520-40C5-878C-C93B3124EF24Q34498098-9B5D4B08-1EA9-4FCE-B749-7B74106D04B7Q34814723-203AD0EA-F614-4008-9A39-A8AFAB6749FCQ35296474-33391606-4608-488D-816B-C6C6D74FB317Q35597112-0FCEEC9E-B673-49A9-8BE3-19492462E801Q35763410-A4E8DFE2-EBBD-4BC6-BA4B-DB389D3CE21BQ35764217-52457CFC-2F6D-4844-BDA1-8EF9B4F82E38Q36055579-52661719-A93C-49D5-B24A-BB5DBD786DADQ36115675-E799269F-439F-4393-AF0C-7F0945741893Q36231743-E7C77728-7362-4FF1-87E2-4C7BC4F27A3FQ36394885-5E01201B-59FC-4A27-8EDE-515ED75842B7Q36508209-207AAB1B-911B-4DE6-AB90-8D3309F6794EQ36755508-141D3D46-A4DD-4B92-8AB3-7036C03C2966Q37339902-5EB8FB7A-C823-40E6-B0B0-E8C8DC5327CF
P50
description
onderzoeker
@nl
name
Reuben Lotan
@ast
Reuben Lotan
@en
Reuben Lotan
@es
Reuben Lotan
@nl
Reuben Lotan
@sl
type
label
Reuben Lotan
@ast
Reuben Lotan
@en
Reuben Lotan
@es
Reuben Lotan
@nl
Reuben Lotan
@sl
prefLabel
Reuben Lotan
@ast
Reuben Lotan
@en
Reuben Lotan
@es
Reuben Lotan
@nl
Reuben Lotan
@sl
P106
P21
P31
P569
2000-01-01T00:00:00Z